GLI
NKTR icon

Guardian Life Insurance’s Nektar Therapeutics NKTR Stock Holding History

Guardian Life Insurance’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-34
Closed -$9K – 528
2019
Q3 		$9K Buy
34
+1
+3% +$367 ﹤0.01% 525
2019
Q2 		$18K Hold
33
– – ﹤0.01% 499
2019
Q1 		$17K Hold
33
– – ﹤0.01% 504
2018
Q4 		$16K Hold
33
– – ﹤0.01% 492
2018
Q3 		$30K Buy
33
+3
+10% +$2.56K ﹤0.01% 435
2018
Q2 		$22K Buy
+30
New +$34.6K ﹤0.01% 476

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Guardian Life Insurance's NKTR Position: Q4 2019 in Review

Guardian Life Insurance sold out of Nektar Therapeutics (NKTR) in Q4 2019, closing a stake of 34 shares — an estimated $9K sold.

Guardian Life Insurance first reported a position in NKTR in Q2 2018 and held it in 6 quarters. The position peaked at $30K in Q3 2018. 281 funds tracked by Wall St. Rank hold NKTR as of Q4 2019.

  • Guardian Life Insurance reported no remaining Nektar Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Guardian Life Insurance sold 34 Nektar Therapeutics shares in Q4 2019, an estimated $9K.
  • Guardian Life Insurance first reported a position in Nektar Therapeutics in Q2 2018 and held it in 6 quarters.
  • Guardian Life Insurance's Nektar Therapeutics position peaked at $30K in Q3 2018.
  • 281 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2019.

Based on Guardian Life Insurance's 13F filing for Q4 2019, filed 11 Feb 2020.